Foxx Life Sciences12.01.20
Mark Robillard has joined Foxx Life Sciences as senior vice president of Global Sales and Business Development.
Robillard brings industry knowledge and experience in all facets of the life science tools industry, with a focus on service and supporting customers. Most recently, he worked as senior partner and practice leader at MKA Insights LLC. Prior to that, he led a portfolio management team at VWR Scientific (now part of Avantor) responsible for a $600+ million product portfolio, globally.
“Foxx is a company founded on product innovation and customer service,” commented Thomas Taylor, president and CEO. “Mark joins our newly appointed senior leadership team of Greg Bousquet, COO and Stephanie Aznoian, CFO and will lead the commercial efforts of Foxx as we continue to service and support our growing customer needs.”
“Foxx Life Sciences has built an incredible brand in a short number of years with a reputation for high quality and innovation,” Robillard added. “I am very proud and excited to lead the commercial team supporting our traditional research distributors and customers as well as expanding our position in the high growth, single use market that supports cell and gene therapy, vaccine production and all phases of biomanufacturing.”
Robillard brings industry knowledge and experience in all facets of the life science tools industry, with a focus on service and supporting customers. Most recently, he worked as senior partner and practice leader at MKA Insights LLC. Prior to that, he led a portfolio management team at VWR Scientific (now part of Avantor) responsible for a $600+ million product portfolio, globally.
“Foxx is a company founded on product innovation and customer service,” commented Thomas Taylor, president and CEO. “Mark joins our newly appointed senior leadership team of Greg Bousquet, COO and Stephanie Aznoian, CFO and will lead the commercial efforts of Foxx as we continue to service and support our growing customer needs.”
“Foxx Life Sciences has built an incredible brand in a short number of years with a reputation for high quality and innovation,” Robillard added. “I am very proud and excited to lead the commercial team supporting our traditional research distributors and customers as well as expanding our position in the high growth, single use market that supports cell and gene therapy, vaccine production and all phases of biomanufacturing.”
